Tumour mutational burden: primary versus metastatic tissue creates systematic bias.

ABSTRACT: Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, which creates a potential for systematic bias. The predominant source is either primary or metastatic tumour tissue. Primary tumours are more heterogeneous and reflect a longer period of tumour evolution, whereas metastases tend to have a more monoclonal structure and potentially different TMB scores. Studies to date measuring TMB have used a heterogeneous set of primary and metastatic tissues, which may explain some of the variability in predictive TMB values across studies. This paper presents data to show that there is a systematic difference whereby me

SUBMITTER: Schnidrig D 

PROVIDER: S-EPMC9216665 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature